Day: February 13, 2025

Quarterly Revenues of $6.0 million and Net Income of $0.9 million MISSISSAUGA, Ontario, Feb. 13, 2025 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its first quarter of fiscal 2025 ended December 31, 2024 (“Q1”). Results for Q1 demonstrated the results of ongoing efforts to increase recurring sales of Microbix’s diagnostic-test related ingredients and devices businesses, work that resulted in a 40% year-over-year increase in such revenues and material net income for the quarter. Management DiscussionResults for Q1 show robust growth in recurring sales of Microbix’s test ingredients (“Antigens”) and test quality assessment products (“QAPs™”), which exceeded C$ 6.0 million (collectively up by 40% for Q1 versus prior...

(All amounts in release are in Canadian dollars) OTTAWA, Ontario, Feb. 13, 2025 (GLOBE NEWSWIRE) — Calian® Group Ltd. (TSX:CGY), a diverse products and services company providing innovative healthcare, communications, learning and cybersecurity solutions, today released its results for the first quarter ended December 31, 2024. Q1-25 Highlights:Revenue up 3% to $185 million Gross margin at 31.8%, slightly down from 32.5% last year Adjusted EBITDA1 of $18 million, down from $21 million last year Operating free cash flow1 of $13 million, down from $17 million last year Net debt to adjusted EBITDA1 ratio of 0.6x Repurchased 101,350 shares in consideration of $4.9 million Guidance reiterated Announced new U.S. subsidiary to focus on U.S. government and defence   Financial Highlights Three months ended(in millions of $,...

Distributable Earnings Before Realizations Increased 15% to a Record $4.9 billion or $3.07 Per Share Quarterly Dividend Raised by 13% BROOKFIELD, NEWS, Feb. 13, 2025 (GLOBE NEWSWIRE) — Brookfield Corporation (NYSE: BN, TSX: BN) announced record financial results for the year ended December 31, 2024. Nick Goodman, President of Brookfield Corporation, said, “We delivered record financial results in 2024, with strong contributions from each of our businesses. Our asset management business had inflows of over $135 billion, our wealth solutions business is now firmly established as a top-tier annuity writer in the U.S., and our operating businesses continue to generate high-quality and stable cash flows.” He continued, “We expect the positive momentum in each of our businesses to continue this year. Our access to scale capital remains...

– Filed for Regulatory Approval of Mitapivat (PYRUKYND®) for the Treatment of Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia in U.S., European Union, Kingdom of Saudi Arabia and United Arab Emirates; PDUFA Goal Date of September 7, 2025 – – Completed Enrollment for Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease; Topline Results Expected in Late 2025, with Potential U.S. Commercial Launch in 2026 – – Early- and Mid-Stage Pipeline Offers Strong Foundation for Innovation and Growth – – PYRUKYND Net Revenue of $10.7 Million in Q4; Cash, Cash Equivalents and Marketable Securities of $1.5 Billion as of December 31, 2024 – CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK)...

–Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater fat loss and improvement of physical function– — The Independent Data Monitoring Committee met this week on February 10, 2025 to evaluate the unblinded safety Phase 2b QUALITY data and recommended to continue the QUALITY extension study as designed– –Topline results of the Phase 2b extension maintenance study to reduce fat regain following discontinuation of GLP-1 RA are expected in the second quarter of calendar 2025– –Company announces new cardiometabolic indication for sabizabulin to treat inflammation in atherosclerotic coronary artery disease– –Company sold the FC2 Female Condom®...

TROY, Mich., Feb. 13, 2025 (GLOBE NEWSWIRE) —  Kelly (Nasdaq: KELYA, KELYB), a leading specialty talent solutions provider, today announced fourth-quarter and full-year 2024 earnings.Q4 revenue of $1.2 billion, down 3.3% year-over-year reflecting the previously disclosed dispositions and acquisitions, and up 4.4% on an organic basis. Full-year revenue of $4.3 billion, down 10.4% as reported and up 0.5% on an organic basis. Q4 operating loss of $56.7 million on $80.8 million non-cash impairment charges; $29.2 million of operating income on an adjusted basis, up 32% versus the prior year period Q4 adjusted EBITDA of $43.5 million, up 34% versus the prior year; adjusted EBITDA margin increased 110 basis points versus the prior year period to 3.7% Full-year operating loss of $15.1 million resulting from non-cash impairment charges;...